Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abrdn Physical Platinum Shares ETF (PPLT) vs 10X Genomics Inc (TXG) Price & Performance

Abrdn Physical Platinum Shares ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Abrdn Physical Platinum Shares ETF vs 10X Genomics Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $17.1, while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.

PPLTTXG
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$25.23$67.29
52-Week Low
$12.38$11.34
Market Cap
$8.55B
Enterprise Value
$8.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abrdn Physical Platinum Shares ETF

PPLT (abrdn Platinum ETF Trust) trades at $16.46, down 0.24% with a bullish technical signal from moving averages. The ETF tracks physical platinum prices, which have lagged behind gold and silver's recent rally. Recent news highlights platinum's potential catch-up trade opportunity as price ratios suggest potential mean reversion. Technical indicators show mixed signals with neutral oscillators but strong trend strength from ADX.

The outlook suggests potential upside as platinum seeks to close its performance gap with other precious metals. Key risks include commodity price volatility and macroeconomic factors affecting industrial demand. Investment opportunity lies in platinum's historical tendency for mean reversion and its dual role as both precious metal and industrial commodity.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abrdn Physical Platinum Shares ETF

PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.

Read more on PPLT

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG